To include your compound in the COVID-19 Resource Center, submit it here.

NN1952: Development discontinued

Novo Nordisk announced in its 1Q11 earnings that it discontinued development of NN1952

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE